Targets › IL1A
2 programs from 2 companies in 9 trials: 7 Phase 2, 1 Phase 1, 1 Phase 3; Oncology, Immunology; next expected readout Dec 2026.
Cytokine constitutively present intracellularly in nearly all resting non-hematopoietic cells that plays an important role in inflammation and bridges the innate and adaptive immune systems. After binding to its receptor IL1R1 together with its accessory protein IL1RAP, forms the high affinity interleukin-1 receptor complex. (UniProt, P01583)
Open in Phaseline: the race on IL1A, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| AbbVie | Lutikizumab Interleukin-1 alpha inhibitor; Interleukin-1 beta inhibitor | IL1A, IL1B | Phase 3 | Hidradenitis Suppurativa; Rheumatoid Arthritis; Atopic Dermatitis; Ulcerative Colitis … | Dec 2026 |
| Centre Georges Francois Leclerc | XB2001 anti-IL-1α true human antibody | IL1A | Phase 1 | Metastatic Colorectal Cancer | – |
Hidradenitis Suppurativa (3) Metastatic Colorectal Cancer (1) Rheumatoid Arthritis (1) Atopic Dermatitis (1) Ulcerative Colitis (1) Psoriatic Arthritis (1) Crohn's Disease (1)
small molecule (1), antibody (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.